PRE
PRENETICS GLB (PRE)
NASDAQ
$21.17+$0.20 (+0.95%)
Price as of Jun 03, 2026 6:43 PM EDT
  • N/A
    Market Cap
  • 178.49%
    1-Year Change
  • Diagnostics & Research
    Industry

Key Performance

More
  • Earnings Score: N/A
  • Momentum Score: 54
  • True Yield: N/A
  • Financial Health Score: N/A
TradeSmith Loading

Latest Research & News

Prenetics' IM8 Partners with Superpower to Personalize the Future of Supplementation

Prenetics Global Limited's IM8 brand has partnered with Superpower to create an integrated health platform combining clinical-grade supplements with comprehensive blood biomarker testing. IM8 90-day subscribers can access Superpower's annual blood testing membership for $49 (75% discount), while Superpower members gain access to IM8's Daily Ultimate Essentials at preferred rates. The partnership aims to provide measurable proof of supplement efficacy through a closed-loop testing and supplementation system.

03/24/2026, 11:00 AM • GlobeNewswire

Personalized Nutrition Market Set to Reach $30.94 Billion by 2030 at 14.4% CAGR | Asia Pacific Emerging as a High-Growth Hub

The global personalized nutrition market is projected to grow from $15.79 billion in 2025 to $30.94 billion by 2030 at a 14.4% CAGR. Digital tools and active measurement technologies are the fastest-growing segments, while Asia Pacific emerges as a high-growth regional hub driven by expanding middle class, rising lifestyle diseases, and rapid digital health adoption.

03/11/2026, 10:00 AM • GlobeNewswire

Prenetics Completes $70 Million Insighta Sale to Tencent, Bolstering Balance Sheet to $171.1 Million in Total Adjusted Liquidity

Prenetics Global Limited completed the sale of its 35% equity interest in Insighta to Tencent for $70 million in cash, bringing total adjusted liquidity to $171.1 million. The company operates with zero debt and plans to use the proceeds to accelerate IM8's global expansion. IM8, co-founded with David Beckham, has achieved over $100 million in annualized recurring revenue within 11 months and is sold in more than 30 countries.

02/17/2026, 8:00 AM • GlobeNewswire

Prenetics Global Limited Announces Proposed Public Offering

Prenetics Global Limited is launching a public offering of shares to fund global expansion of its IM8 health supplement brand and strategic Bitcoin accumulation, with plans to continue purchasing 1 Bitcoin daily.

10/24/2025, 8:30 PM • GlobeNewswire

Peers

Statistics

More
Day Range
$19.51
$21.07
$20.97
1-Year Range
$7.01
$22.15
$20.97
Latest Close$20.97
Change
+$0.58 (+2.77%)
Volume274,960
Shares Outstanding16.9M
P/E (TTM)-7.87
Diluted EPS (TTM)-$2.68

Information as of 06/02/2026

Company Profile

PRENETICS GLOBAL LTD
PRENETICS GLOBAL LTD
https://www.prenetics.com
N/A
Market Cap
-$40.0M
Net Income
Sector: Healthcare
Industry: Diagnostics & Research
Unit 703-706, K11 Atelier King?s Road, Quarry Bay, Hong Kong
852 2210 9588

Prenetics Global Limited, a health sciences company, focuses on consumer health in Hong Kong and the United States. It sells health and wellness products under the IM8 brand name; and provides fulfillment and distribution services for sports nutrition products under the Europa brand. The company is also involved in the operation of CircleDNA, a consumer genetic testing brand that uses next-generation sequencing (NGS) technology to provide insights into health, wellness, and genetic predispositions. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.

Key Executives

  • Samantha Kwok
  • Sheng Wu Yeung
  • Joel Neoh
  • David Eric Vanderveen
  • Hoi Chun Lo

Current Ownership Distribution

  • Mutual Funds94.5M (59.87%)
  • Institutions61.6M (39.01%)
  • Insiders1.8M (1.12%)
  • Other0 (0.00%)